Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse
European research council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862)
Received: 18 February 2020
Accepted: 18 May 2020
First Online: 26 May 2020
Ethics approval and consent to participate
: All procedures for experiments were performed in accordance with the ethical committee in Gothenburg (ethical permit 5.8.18-11305/2018) and followed the guidelines of the Swedish National Board for Laboratory Animals.
: Not applicable.
: HZ has served at scientific advisory boards for Samumed, CogRx, Roche Diagnostics, Denali, and Wave, has given lectures in symposia sponsored by Fujirebio, AlzeCure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. AK, MK, PK, and SI were all employed by Cellectricon AB at the time for the experiments. All other authors declare that they have no competing interests.